GlassScriptPhysician profile
Christopher Todd Yohn
NPI 1063945533
$1,502.43
in general payments reported to CMS, 2019-2025
23 companies · $785 in 2025
The $785 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $111 · 2024: $606 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $314.93 | 2023-2025 | Vraylar, Mavyret |
| Gilead Sciences, INC. | $270.05 | 2024-2025 | |
| Indivior INC. | $148.98 | 2023-2025 | Sublocade |
| Phathom Pharmaceuticals, INC. | $105.29 | 2024-2025 | Voquezna |
| Braeburn INC. | $98.73 | 2024-2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $75.58 | 2024-2025 | |
| Alkermes, INC. | $67.36 | 2023-2025 | Vivitrol, Vivitrol |
| Edwards Lifesciences Corporation | $50.30 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Exact Sciences Corporation | $48.44 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $47.19 | 2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $41.84 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $35.23 | 2023-2024 | Spravato |
| Merck Sharp & Dohme LLC | $22.66 | 2024 | Delstrigo, Pifeltro |
| Astellas Pharma US INC | $20.72 | 2025 | Veozah |
| Corcept Therapeutics | $19.55 | 2025 | Korlym |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $19.18 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $18.36 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $17.99 | 2024 | Mounjaro |
| Pfizer INC. | $17.21 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.11 | 2025 | Caplyta |
| Lundbeck LLC | $15.89 | 2025 | Rexulti |
| Novo Nordisk INC | $15.41 | 2025 | Wegovy |
| Axsome Therapeutics, INC. | $14.43 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Yohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.